RecruitingNCT04340024
Discovery of Biomarkers for Intrinsic Radiation Sensitivity in Cancer Patients
Sponsor
National Cancer Centre, Singapore
Enrollment
5,000 participants
Start Date
Sep 30, 2015
Study Type
OBSERVATIONAL
Conditions
Summary
Patients with cancers that are sensitive to radiotherapy treatment and/or patients who have experienced severe acute/ late side effects to radiotherapy will be recruited to the study. Blood and/or matched tumour-normal tissue pairs will be collected. Blood and/or tissue samples will be processed and studied for genetic and biochemical markers that have potential to be used for predicting sensitivity to radiation.
Eligibility
Min Age: 21 YearsMax Age: 99 Years
Inclusion Criteria2
- Patients with severe side effects from radiotherapy
- Patients with a type of cancer that is associated with sensitivity to radiotherapy
Exclusion Criteria1
- Age of patient must be between 21 (inclusive) and 99 (exclusive)
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04340024
Related Trials
64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer
NCT0697084728 locations
Mechanisms of Resistance to PSMA Radioligand Therapy
NCT054354953 locations
Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program
NCT0489583916 locations
INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis
NCT073986901 location
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
NCT060968701 location